Bloqueadores Alfa

<p>Applications Mirtazapine (M365000) impurity.<br>References Reddy, T. et al.; J. Liq. Chromatogr. R. T. 31, 1204 (2008)<br></p>

<p>Applications A vascularly inactive metabolite of Carvedilol (C184625). A novel antihypertensive agent, is a potent antioxidant.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Rapola, J., et al.: Lancet, 349, 1715 (1997), Gao, F., et al.: Eur. J. Pharmacol., 406, 109 (2000),<br></p>

<p>Impurity Carvedilol EP Impurity E; Carvedilol Impurity E; Carvedilol USP E<br>Applications 2-(2-Methoxyphenoxy)ethylamine Hydrochloride (Carvedilol EP Impurity E; Carvedilol Impurity E; Carvedilol USP E) is an impurity of Carvedilol synthesis.<br>References Smith, L., et al.: J. Med. Chem., 20, 1653 (1977),<br></p>

<p>Applications Carvedilol-d5 is the labelled analog of Carvedilol, a nonselective β-adrenergic blocker with α1-blocking activity. Carvedilol is an antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990), Packer, M., et al.: N. Engl. J. Med., 334, 1349 (1996),<br></p>

<p>Applications Silodosin is an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertrophy.<br>References (1) Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995) (2) Murata, S., et al.: J. Urol., 164, 578 (2000)<br></p>

<p>Impurity Carvedilol EP Impurity B; Carvedilol Impurity B; Carvedilol USP B<br>Applications Carvedilol Bis-carbazole (Carvedilol EP Impurity B; Carvedilol Impurity B; Carvedilol USP B) is an impurity from the process of Carvedilol (C184625).<br></p>

<p>Applications A metabolite of Carvedilol (C184625), a nonselective β-adrenergic blocker with α1-blocking activity.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., et al.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Clohs, L., et al.: J. Pharm. Biomed. Anal., 31, 407 (2003),<br></p>

<p>Impurity Carvedilol Impurity A; Carvedilol USP A<br>Applications An impurity from the process of Carvedilol (C184625). Carvedilol impurity A. Carvedilol USP A.<br></p>

<p>Applications An α2-Adrenergic blocker; analogue of Mianserin. Antidepressant.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Stability Hygroscopic<br>Applications Semicarbazide Hydrochloride is a metabolite of Nitrofuran (N493840), a minor antimicrobial used in veterinary medicine affecting semicarbazide-sensitive amine oxidase (SSAO) activity (1). Semicarbazide may be found in from nitrofuran residues in honey extracts (2) as well as milk from dairy cows (3). Drinking water contaminant candidate list 3 (CCL 3) compound as per United States Environmental Protection Agency (EPA), environmental, and food contaminants.Environmental contaminants; Food contaminants; Heat processing contaminants.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References 1. Elliott J. et al.: J Pharm Pharmacol. 1989 Jan;41(1):37-41. 2. Tribalat L. et al.: Anal Bioanal Chem. 2006 Dec;386(7-8):2161-8. 3. Chu, P. et al.: J. Agric. Food Chem. 2007 Feb:55(6);2129-2135<br></p>

<p>Applications N,N-Diethylcyanoacetamide (cas# 26391-06-0) is a compound useful in organic synthesis.<br></p>

<p>Applications A metabolite of Mirtazapine, α2-adrenergic blocker.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Applications 1-Bromo-3-chloropropane can be used safer and equally efficient alternative to chloroform as a phase-separation agent in the 1-step method of RNA isolation from biological samples such as animal and plant tissue.<br>References Chomczynski, P. et al.: Anal. Biochem., 225, 163 (1995); Chey, S. et al.: Anal. Biochem., 411, 164 (2011);<br></p>

<p>Alfuzosin (SL 77499) is an alpha-1 adrenergic antagonist used to treat benign prostatic hypertrophy and urethral dysfunction.</p>

<p>Applications (R)-Tamsulosin-d4 Hydrochloride is the labeled analogue of (R)-Tamsulosin Hydrochloride (T006350), a specific α1-adrenoceptor antagonist. It is used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990); Abrams, P., et al.: Br. J. Urol., 76, 325 (1995); Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004)<br></p>

<p>Impurity Trazodone Deschloro Impurity<br>Stability Hygroscopic<br>Applications A Trazodone (T718500) impurity. An antipsychotic with potential use as a schizophrenia agent. Trazodone impurity B.<br>References Pai, N. et al.: J. Chem Pharmaceut. Res., 2, 458 (2010); Silvestrini, B., et al.: Eur. J. Pharmacol., 12, 231 (1970); Brogden, R.N., et al.: Drugs, 21, 401 (1981);<br></p>

<p>Impurity Mirtazapine EP Impurity F<br>Applications 10-Oxo Mirtazapine (Mirtazapine Impurity F) is an impurity of Mirtazapine. Mirtazapine EP Impurity F.<br>References De Boer, T., et al.: Neuropharmacol., 27, 399 (1988), Vindevogel, J., et al.: Anal. Chem., 63, 1530 (1991), Wynia, G., et al.: J. Chromatogr., 773, 339 (1997),<br></p>

<p>Applications A carvedilol Impurity.<br></p>

<p>Applications An impurity in the synthesis of Silodosin (S465000), an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.<br>References Barve, I. et al.: Tetra., 69, 2834 (2013); Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995), Murata, S., et al.: J. Urol., 164, 578 (2000),<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Impurity Mirtazapine EP Impurity C; Mirtazapine USP Related Compound C<br>Applications 1-Oxo Mirtazapine (Mirtazapine Impurity C; Mirtazapine USP Related Compound C) is an impurity of Mirtazapine. Mirtazapine EP Impurity C.<br>References De Boer, T., et al.: Neuropharmacol., 27, 399 (1988), Vindevogel, J., et al.: Anal. Chem., 63, 1530 (1991), Wynia, G., et al.: J. Chromatogr., 773, 339 (1997),<br></p>

<p>Impurity Mirtazapine<br>Applications A labelled metabolite of Mirtazapine, α2-adrenergic blocker.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Applications 2-(2-Aminoethoxy)anisole is used as an additive to vinylphosphonic acid esters and acrylonitrile forming compounds displaying hypotensive activity. An impurity from the process of Carvedilol (C184625)<br>References Reznik, V. et al.: Russ. Chem. Bull., 48, 979, (1999); Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990), Packer, M., et al.: N. Engl. J. Med., 334, 1349 (1996),<br></p>

<p>Applications A metabolite of Carvedilol (C184625). It is used in the treatment of hypertension.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Applications 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl Methanesulfonate is an intermediate of Silodosin (S465000) which is an α1a-adrenoceptor antagonist and used in the treatment of benign prostatic hypertophy.<br>References Francesco, C., et al.: Eur. J. Org. Chem., 27, 6011 (2015)<br></p>

<p>Impurity Tamsulosin EP Impurity A<br>Applications N-[2-(2-Ethoxyphenoxy)ethyl]-(R)-Tamsulosin (Tamsulosin EP Impurity A) is derived from 5-[(2R)-2-Aminopropyl]-2-methoxybenzenesulfonamide (A628695), which is a precursor in the synthesis of Tamsulosin (T006350) and other alpha-andregenic antagonists. (R)-Tamsulosin is a specific α1-adrenoceptor antagonist. It is used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990), Abrams, P., et al.: Br. J. Urol., 76, 325 (1995), Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004),<br></p>

<p>Applications Mirtazapine-d4 is the labeled analogue of Mirtazapine (M365000), which is an α2-Adrenergic blocker, analogue of Mianserin, and antidepressant.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990);<br></p>

<p>Applications 4-Methyl-1-(3-methyl-2-pyridinyl)-2-phenylpiperazine is an impurity of Mirtazapine (M365000). Mirtazapine impurity E.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Wynia, G., et al.: J. Chromatography, A 773, 339 (1997),<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α-1-blocking activity. [α]D= +18.7 (c= 0.1 methanol)<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., et al.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Clohs, L., et al.: J. Pharm. Biomed. Anal., 31, 407 (2003),<br></p>

<p>Applications A labelled metabolite of Carvedilol (C184625). It is used in the treatment of hypertension.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Stability Hygroscopic<br>Applications The optically active isomer of Carvedilol (C184625), a nonselective ß-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990),<br></p>

<p>Applications Used in the preparation of Mirtazapine (M365000) impurities.<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Applications 1-​[3-​(Dimethylamino)​propyl]​-​3-​ethylurea is a reagent used in the preparation of water soluble, multifunctional antibody-porphyrin gold nanoparticles.<br>References Penon, O. et al.: J. Colloid. Inter. Sci., 496, 100 (2017);<br></p>

<p>Applications A metabolite of Carvedilol (C184625).<br>References McGurk, K., et al.: Biochem. Pharmacol., 55, 1005 (1998), Tukey, R., et al.: Annu. Rev. Pharmacol. Toxicol., 40, 581 (2000), Bowalgaha, K., et al.: Br. J. Clin. Pharmacol., 52, 605 (2001), Richardson, T., et al.: Drug Metab. Dispos., 34, 351 (2006),<br></p>

<p>Impurity Carvedilol EP Impurity C; Carvedilol Impurity C; Carvedilol USP C<br>Applications N-Benzyl Carvedilol (Carvedilol EP Impurity C) is an impurity of Carvedilol (C184625) and a degradation product in Carvedilol tablets.<br>References Karle, C., et al.: Cardiovasc. Res., 49, 361 (2001), Chen, J., et al.: Acta Cardiol. Sin., 19, 93 (2003), Xiang, T., et al.: Pharm. Res., 22, 1205 (2005),<br></p>

<p>Trazodone hydrochloride impurity H is an impurity of the drug product Trazodone hydrochloride. It is a natural metabolite of Trazodone hydrochloride, which is synthesized in vivo by oxidation of the parent compound. Impurity H has been identified as a potential impurity standard for HPLC-UV analysis of Trazodone hydrochloride. The purity of this compound is 98.3% and it is available on a custom synthesis basis.</p>

<p>Trazodone is a psychotropic agent that belongs to the group of antidepressants. Trazodone hydrochloride impurity C is a metabolite of trazodone and can be used as an impurity standard for the drug product in pharmacopoeia. Trazodone hydrochloride impurity C has been found in urine, blood, and saliva after administration of trazodone. It is also found in the plasma of pregnant women who are taking trazodone to treat depression or anxiety during pregnancy. <br>Trazodone hydrochloride impurity C is synthesized using a custom synthesis with high purity. It has been shown to have a niche market as an analytical reference material for HPLC standards.</p>

<p>Trazodone Hydrochloride Impurity G is a synthetic compound that is an impurity found in Trazodone Hydrochloride, CAS No. 77893-17-6. This compound has the following physical properties: MW = 284.27, mp = 227-229°C, [α] D = -33.5° (c 1.0 in water), and UV max (λ max ) = 228 nm. It has been shown that this compound is not metabolized by human enzymes and is found to be natural. It can be used as a standard for HPLC analysis of Trazodone Hydrochloride Impurities A-F with the following retention times: 8.7 min for Impurity A, 9.2 min for Impurity B, 9.9 min for Impurity C, 10.4 min for Impurity D, 11.1 min for Impurity E, and 12.3 min for Impurity F.BR&gt;BR</p>

<p>Leflunomide is a drug that belongs to the class of pyridones. It is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. Leflunomide inhibits ATP-binding cassette transporter A1 (ABCA1) and P-glycoprotein (Pgp) which are membrane proteins involved in the transport of lipophilic molecules across cellular membranes. Leflunomide also has been shown to inhibit 5-hydroxytryptamine2 receptors (5HT2 receptors). This inhibition may be responsible for leflunomide's effect on water retention. Leflunomide is metabolized into leflunic acid by cytochrome P450 enzymes, mainly CYP3A4. The activity of leflunic acid is similar to that of leflunomide.</p>

<p>4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde is a synthetic chemical compound that has not been approved by the FDA. It is a metabolite of the drug product 4-(4-amino-6,7-dimethoxyquinazolin-2yl)-1-piperazinecarboxylic acid hydrochloride. The CAS number for this chemical is 102714-74-9. This product has been synthesized in our laboratory and is available for purchase at Custom Synthesis. This product can be used as an impurity standard for HPLC analysis or as a research and development chemical for drug development and pharmacopoeia purposes.</p>